Which Company’s Stock is more Profitable? Oclaro, Inc. (OCLR) or ACADIA Pharmaceuticals Inc. (ACAD)

The shares of Oclaro, Inc. (NASDAQ:OCLR) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were among the active stocks of the last trading sessions. Oclaro, Inc. (NASDAQ:OCLR) declined to -0.12% closing at the price of $8.24 whereas the shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) soared 1.02% with the increase of 0.22 points closing at the price of $21.88. Oclaro, Inc. has currently decrease -3.29% in its stock over the period of 6-months while its rival ACADIA Pharmaceuticals Inc. added 17.76% in the previous 6-months.

Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.

Returns and Profitability

Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.

The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of Oclaro, Inc. (NASDAQ:OCLR) is 15.1% while the ROI of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is -67%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, OCLR’s EBITDA Margin is 10.83 whereas ACAD’s is -9.91.

Both the profitability ratios suggest that Oclaro, Inc. (NASDAQ:OCLR) is more suitable investment in terms of profitability and return.

EPS & Surprise Factor

Oclaro, Inc. (NASDAQ:OCLR) reported $0.08/share EPS for the previous quarter where analysts were predicting an EPS to be $0.08/share Thus meeting the analyst Estimates with a Surprise Factor of 0 Percent. While, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported EPS of $-0.5/share in the last quarter. The analysts projected EPS of $-0.58/share depicting a Surprise of 13.8 Percent.

Taking a look at Earnings per Share, ACADIA Pharmaceuticals Inc. tends to be beating the analyst estimates more than Oclaro, Inc.. so ACAD is more profitable than OCLR.

Technical Analysis of Oclaro, Inc. & ACADIA Pharmaceuticals Inc.

Moving average convergence divergence (MACD) shows that Oclaro, Inc. (NASDAQ:OCLR) is on a PRICE RELATIVITY trend While ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the Oclaro, Inc. was in BULLISH territory and ACADIA Pharmaceuticals Inc. was in BULLISH territory.

OCLR’s current statistics gauge that the stock candle is BULLISH with HIGH volatility. While ACAD’s candle is BEARISH with HIGH.

EPS Growth Rate: OCLR’s 14% versus ACAD’s 25.9%

Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of Oclaro, Inc. (NASDAQ:OCLR) is predicted at 14% while ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands at 25.9%. These numbers suggest that ACAD is more suitable investment in terms of EPS growth rate.

Financial Risk and Liquidity Concerns

The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of OCLR stands at 5 while ACAD is at 6.1 whereas the debt ratio of the prior is 0.01 while the debt ratio of the later is 0.

The values of the both ratios suggest that one is more liquid and other investment is more risk free.

Analyst Recommendations

While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 2.7 for OCLR and 2.1 for ACAD which means OCLR has Hold rating whereas ACAD has Hold rating.

Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for OCLR is $9.18 which is 10.24% of its current price while ACAD has price target of 33.44 which is 34.57% of its current price.

Valuation Ratios

Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.

OCLR currently has price to earning P/E ratio of 14.53 whereas ACAD has 0 while the forward P/E ratio for the prior stands at 15.91 and for the later it depicts the value of 0.

The price to Book P/B for OCLR is 2.37, Price to Sale is at 2.6 and for ACAD these ratios stand at 10.32 and 14.54.